Mesoblast (MESO) earnings history
Most recent quarter
- Fiscal period
- Q4 2023
- Period end
- Jun 30, 2023
- EPS actual
- −$0.27
- EPS estimate
- −$0.28
- EPS surprise
- +4.12%
- Revenue surprise
- −20.28%
- Revenue
- $1.9M
- Revenue estimate
- $2.4M
- Reported
- Aug 31, 2023
The most recent results in this table are Mesoblast's fiscal Q4 2023, reported on August 31, 2023. The company posted a loss of $0.27 per share, narrower than the expected $0.28 loss, a 4.12% beat. Revenue was $1.9 million, 20.28% below the $2.4 million estimate. In fiscal Q4 2022 the loss was $0.32 per share on revenue of $2.2 million.
Every quarter in the table is a loss. The annual loss narrowed from $1.54 per share in fiscal 2021 to $1.34 in fiscal 2022 and $1.05 in fiscal 2023. Quarterly revenue has been small, between $1.3 million and $2.4 million in every quarter since fiscal Q1 2021. The revenue high here is $12.2 million, in fiscal Q3 2020. Revenue estimates were missed by wide margins in several quarters, such as fiscal Q1 2021, at $1.3 million against $40.6 million expected. Mesoblast beat the EPS estimate in 6 of the 14 quarters shown, including 5 of the last 8.
The table holds no results after the August 2023 report, so fiscal 2024 and later years are not shown here. In the years it covers, fiscal Q4 results came at the end of August and fiscal Q1 results in late November.
Earnings history
| Period | Reported | EPS estimate | EPS actual | Surprise | Revenue | Filing |
|---|---|---|---|---|---|---|
| Q4 2023 | Aug 31, 2023 | −$0.28 | −$0.27 | +4.12% | $1.9M | SEC |
| Q3 2023 | May 26, 2023 | −$0.31 | −$0.24 | +23.79% | $1.9M | SEC |
| Q2 2023 | Feb 28, 2023 | −$0.27 | −$0.31 | −18.57% | $2.1M | SEC |
| Q1 2023 | Nov 28, 2022 | −$0.31 | −$0.23 | +25.61% | $1.5M | — |
| Q4 2022 | Aug 31, 2022 | −$0.19 | −$0.32 | −65.84% | $2.2M | — |
| Q3 2022 | Jun 3, 2022 | −$0.26 | −$0.31 | −21.48% | $2.0M | — |
| Q2 2022 | Feb 25, 2022 | −$0.39 | −$0.38 | +1.63% | $2.4M | — |
| Q1 2022 | Nov 26, 2021 | −$0.37 | −$0.33 | +9.34% | $2.4M | — |
| Q4 2021 | Aug 31, 2021 | −$0.18 | −$0.30 | −64.09% | $2.0M | — |
| Q3 2021 | Jun 4, 2021 | −$0.08 | −$0.42 | −448.35% | $1.9M | — |
| Q2 2021 | Mar 2, 2021 | −$0.24 | −$0.42 | −72.90% | $2.2M | — |
| Q1 2021 | Nov 23, 2020 | −$0.07 | −$0.40 | −501.20% | $1.3M | — |
| Q4 2020 | Aug 31, 2020 | −$0.33 | −$0.57 | −70.48% | $701,000.00 | — |
| Q3 2020 | May 29, 2020 | −$0.35 | −$0.27 | +21.96% | $12.2M | — |
Quarterly revenue
Frequently asked questions
When did Mesoblast (MESO) last report earnings?
Mesoblast last reported on Aug 31, 2023, covering fiscal Q4 2023.
Did MESO beat earnings estimates?
Yes. Mesoblast reported EPS of −$0.27 for Q4 2023 against a −$0.28 estimate — a 4.12% beat.
How much revenue did MESO report last quarter?
Mesoblast reported $1.9M in revenue for Q4 2023, against a consensus estimate of $2.4M.
Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.